Fernando Nalesso Aguiar

Fernando Nalesso Aguiar

Auto-generated profile, based on publicly available information

Fernando Nalesso Aguiar

Pathology Division, Instituto do Câncer do Estado de São Paulo (ICESP), Brazil

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 March 2025 in Clinics
Verified
Journal Article
Open access
ADAline Rocha Donato
Aline Rocha Donato
RGRodrigo Goncalves
Rodrigo Goncalves
JMJonathan Yugo Maesaka
Jonathan Yugo Maesaka
FAFernando Nalesso Aguiar
Fernando Nalesso Aguiar
José Maria  Soares-JrJosé Maria Soares-Jr
José Maria Soares-Jr
EBEdmund Chada Baracat
Edmund Chada Baracat
Phyllodes Tumor (PT) of the breast is a rare type of fibroepithelial neoplasm, classified into benign, borderline, and malignant subtypes. These tumors are known to be locally aggressive and have an inherent potential for Local Recurrence (LR), even after adequate surgical treatment. Establishing strategies to reduce LR has become increasingly important, as 21 % to 36 % of patients experience disease recurrence despite achieving negative surgical margins. Although surgical resection of the lesion is the gold standard treatment for all subtypes of phyllodes tumors, the ideal extent of the surgical margin remains a topic of debate with no consensus in the literature. Adjuvant radiotherapy is suggested as a tool to improve local control of the disease and reduce the recurrence rate; however, published data on this approach are currently conflicting. In this review paper, the authors will provide a detailed analysis of the current evidence on the diagnosis, treatment, follow-up, outcomes, and future perspectives of phyllodes tumors.

1 January 2021 in Clinics
Verified
Journal Article
Open access
MKMárcia Farina Kamilos
Márcia Farina Kamilos
LALana Maria Aguiar
Lana Maria Aguiar
VBValéria Holmo Batista
Valéria Holmo Batista
CRCristiane Lima Roa
Cristiane Lima Roa
FAFernando Nalesso Aguiar
Fernando Nalesso Aguiar
EBEdmund Chada Baracat
Edmund Chada Baracat
To assess the clinical response to and the histomorphometric effects of microablative fractional radiofrequency (MFR) in women with symptomatic vulvar lichen sclerosus (VLS).This was a pilot study on the use of MFR for the treatment of VLS. Upon recruitment ...

1 July 2022 in European Journal of Breast Health
Verified
Journal Article
Closed access
PSPriscila de Medeiros Souza
Priscila de Medeiros Souza
FCFilomena Marino Carvalho
Filomena Marino Carvalho
FAFernando N. Aguiar
Fernando N. Aguiar
DGDebora de Melo Gagliato
Debora de Melo Gagliato
ABAlfredo Carlos Simões Dornellas de Barros
Alfredo Carlos Simões Dornellas de Barros
This study evaluated the frequency of GATA-binding protein 3 (GATA3) expression in early breast cancer and its relationship with histopathological and immunohistochemical parameters. GATA3 was analysed by immunohistochemistry in histological sections of tumors from 105 female patients, with histological diagnosis of invasive breast carcinoma (BC), at clinical stages I, II and IIIA, who underwent primary surgical treatment. GATA3 nuclear expression was determined as the percentage of positive tumor cells and further categorized as high (positive expression in more than 95% of cells) or non-high (negative or low positive expression in up to 95% of tumor cells). GATA3 expression was analysed according to the patient age, tumor and node pathological stage, histological type, histological and nuclear grade, lymphovascular invasion, and estrogen receptor (ER), progesterone receptor (PR), androgen receptor (AR), human epidermal growth factor 2 (HER2) status, and Ki-67 expression. GATA3 expression was positive in 103 cases (98.1%). High expression was significantly associated with low histological and nuclear grade, positive hormonal receptors, and less proliferative activity based on Ki-67 expression. A prominent feature was that 94.7% of the ER-positive/HER2-negative cases presented high-GATA3 expression, as 94.0% of the tumors showing high-GATA3 were ER-positive. In ER-negative/HER2-positive or ER-negative/HER2- negative, high-GATA3 was present in 25% while 75% were non-high-GATA3 compared with ER-positive/HER2- negative (4.1%) and ER-positive/HER2-positive (20%). Proliferative activity in triple-negative breast cancer tended to be higher among tumors with low-GATA3, irrespective of AR expression. In the group of ER-positive/HER2-negative tumors only three cases were low-GATA3 (85% and 80%), both with high proliferative activity. High GATA3 expression is associated with favorable histopathologic and immunohistochemical BC prognostic factors.

24 August 2024 in Breast Cancer Research and Treatment
Verified
Journal Article
Closed access
PDF file
CPCamila Vitola Pasetto
Camila Vitola Pasetto
FAFernando Nalesso Aguiar
Fernando Nalesso Aguiar
MPMarcella Bassan Peixoto
Marcella Bassan Peixoto
MDMaíra Teixeira Dória
Maíra Teixeira Dória
BMBruna Salani Mota
Bruna Salani Mota
RGRodrigo Gonçalves
Rodrigo Gonçalves

7 August 2026 in Journal of Plastic, Reconstructive & Aesthetic Surgery
Verified
Journal Article
Closed access
TUThiago Ueda
Thiago Ueda
AMAlexandre Mendonça Munhoz
Alexandre Mendonça Munhoz
EMEduardo Montag
Eduardo Montag
AOAlberto Yoshikazu Okada
Alberto Yoshikazu Okada
FAFernando Nalesso Aguiar
Fernando Nalesso Aguiar
RGRolf Gemperli
Rolf Gemperli